ESTRO 2024 - Abstract Book

S1991

Clinical - Mixed sites, palliation

ESTRO 2024

Forty- seven older persons aged ≥70 years were included in the study, comprising 28 men (59.6%). Thirty patients (63.8%) had an ECOG performance status of 1. RT was curative in 20 patients (42.5%), adjuvant in 19 cases (40.4%), and combined with hormone therapy in 27 cases (57.4%). The most prevalent cancer site was the prostate (n=22, 46.8%). The description of late toxicity patterns by cancer site is illustrated in Figure 1. A significant proportion of patients, 53%, reported substantial late toxicity. No statistically significant relationship was identified between acute and substantial late toxicity (p=0.095). Substantial late toxicity was more frequently observed in patients who had not undergone prior surgery (p=0.011) and in those with prostate cancer (p<0.001). Of the 22 patients receiving prostatic RT, 19 experienced late toxicity with a RTOG/EORTC grade of 2 or higher, and voiding complaints were the most frequently reported symptom (n=18). Among the 11 patients with breast cancer, 7 exhibited skin/soft tissue